These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17034968)

  • 1. Bioavailability of riboflavin from a gastric retention formulation.
    Ahmed IS; Ayres JW
    Int J Pharm; 2007 Feb; 330(1-2):146-54. PubMed ID: 17034968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citric acid prolongs the gastro-retention of a floating dosage form and increases bioavailability of riboflavin in the fasted state.
    Stops F; Fell JT; Collett JH; Martini LG; Sharma HL; Smith AM
    Int J Pharm; 2006 Feb; 308(1-2):14-24. PubMed ID: 16343829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans.
    Kagan L; Lapidot N; Afargan M; Kirmayer D; Moor E; Mardor Y; Friedman M; Hoffman A
    J Control Release; 2006 Jul; 113(3):208-15. PubMed ID: 16806558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of in vitro and in vivo performance of a colonic delivery system.
    Ahmed IS; Ayres JW
    Int J Pharm; 2011 May; 409(1-2):169-77. PubMed ID: 21382462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified-release capsules containing sodium riboflavin 5'-phosphate.
    Buchholcz G; Kelemen A; Pintye-Hódi K
    Drug Dev Ind Pharm; 2014 Dec; 40(12):1632-6. PubMed ID: 24083326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans.
    Sato Y; Kawashima Y; Takeuchi H; Yamamoto H
    Int J Pharm; 2004 May; 275(1-2):97-107. PubMed ID: 15081141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoscintigraphic evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans.
    Sato Y; Kawashima Y; Takeuchi H; Yamamoto H; Fujibayashi Y
    J Control Release; 2004 Jul; 98(1):75-85. PubMed ID: 15245891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric retention properties of superporous hydrogel composites.
    Chen J; Blevins WE; Park H; Park K
    J Control Release; 2000 Feb; 64(1-3):39-51. PubMed ID: 10640644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites.
    Akiyama Y; Nagahara N; Nara E; Kitano M; Iwasa S; Yamamoto I; Azuma J; Ogawa Y
    J Pharm Pharmacol; 1998 Feb; 50(2):159-66. PubMed ID: 9530983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation.
    Chavanpatil M; Jain P; Chaudhari S; Shear R; Vavia P
    Int J Pharm; 2005 Nov; 304(1-2):178-84. PubMed ID: 16198522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation.
    Xiumin LI; Man GE; Minzi LU; Yinghua J; Dongqin Q
    Curr Drug Deliv; 2015; 12(3):308-13. PubMed ID: 26054534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food intake on the delivery of fluorescein as a model drug in colon delivery capsule after oral administration to beagle dogs.
    Matsuda K; Takaya T; Shimoji F; Muraoka M; Yoshikawa Y; Takada K
    J Drug Target; 1996; 4(2):59-67. PubMed ID: 8894965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of floating riboflavin pellets developed using the melt pelletization process.
    Hamdani J; Goole J; Moës AJ; Amighi K
    Int J Pharm; 2006 Oct; 323(1-2):86-92. PubMed ID: 16815656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of triethanolamine myristate, a fatty acid salt, on the bioavailability of riboflavin in dogs.
    Forusz H; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):589-91. PubMed ID: 9010833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-sensitive sodium alginate hydrogels for riboflavin controlled release.
    Abd El-Ghaffar MA; Hashem MS; El-Awady MK; Rabie AM
    Carbohydr Polym; 2012 Jun; 89(2):667-75. PubMed ID: 24750772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy.
    Pund S; Joshi A; Vasu K; Nivsarkar M; Shishoo C
    Int J Pharm; 2011 Jun; 411(1-2):106-12. PubMed ID: 21458549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs.
    Klausner EA; Lavy E; Stepensky D; Friedman M; Hoffman A
    Pharm Res; 2002 Oct; 19(10):1516-23. PubMed ID: 12425470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.